Employees department of Public Health



L.E. Coffeng MD PhD - click to enlarge
L.E. Coffeng MD PhD
Assistant Professor
Biography Research Interests Projects Publications Working papers Memberships Contact

    1 Clarke NE, Ng-Nguyen D, Traub RJ, et al. A cluster-randomised controlled trial comparing school and community-based deworming for soil transmitted helminth control in school-age children: the CoDe-STH trial protocol. BMC Infect Dis 2019; 19: 822.

    2 Coffeng LE, Stolk WA, Golden A, de Los Santos T, Domingo GJ, de Vlas SJ. Predictive Value of Ov16 Antibody Prevalence in Different Sub-Populations for Elimination of African Onchocerciasis. Am J Epidemiol 2019; 351: 843.

    3 de Carvalho TM, Heijnsdijk EAM, Coffeng L, de Koning HJ. Evaluating Parameter Uncertainty in a Simulation Model of Cancer Using Emulators. Med Decis Mak 2019; 39: 405–13.

    4 Giardina F, Coffeng LE, Farrell SH, et al. Sampling strategies for monitoring and evaluation of morbidity targets for soil-transmitted helminths. PLoS Negl Trop Dis 2019; 13: e0007514.

    5 Hoogerwerf M-A, Coffeng LE, Brienen EAT, et al. New insights into the kinetics and variability of egg excretion in controlled human hookworm infections. J Infect Dis 2019; published online May 11. DOI:10.1093/infdis/jiz218.

    6 Vinkeles Melchers NVS, Coffeng LE, Boussinesq M, et al. Projected number of people with onchocerciasis-loiasis co-infection in Africa, 1995 to 2025. Clin Infect Dis 2019; published online July 13. DOI:10.1093/cid/ciz647.

    7 Bulstra CA, Le Rutte EA, Malaviya P, et al. Visceral leishmaniasis: Spatiotemporal heterogeneity and drivers underlying the hotspots in Muzaffarpur, Bihar, India. PLoS Negl Trop Dis 2018; 12: e0006888.

    8 Coffeng LE, Vaz Nery S, Gray DJ, Bakker R, de Vlas SJ, Clements ACA. Predicted short and long-term impact of deworming and water, hygiene, and sanitation on transmission of soil-transmitted helminths. PLoS Negl Trop Dis 2018; 12: e0006758.

    9 de Vos AS, Stolk WA, de Vlas SJ, Coffeng LE. The effect of assortative mixing on stability of low helminth transmission levels and on the impact of mass drug administration: Model explorations for onchocerciasis. PLoS Negl Trop Dis 2018; 12: e0006624.

    10 Farrell SH, Coffeng LE, Truscott JE, et al. Investigating the Effectiveness of Current and Modified World Health Organization Guidelines for the Control of Soil-Transmitted Helminth Infections. Clin Infect Dis 2018; 66: S253–9.

    11 Le Rutte EA, Chapman LAC, Coffeng LE, et al. Policy Recommendations From Transmission Modeling for the Elimination of Visceral Leishmaniasis in the Indian Subcontinent. Clin Infect Dis 2018; 66: S301–8.

    12 Reuling IJ, van de Schans LA, Coffeng LE, et al. A randomized feasibility trial comparing four antimalarial drug regimens to induce Plasmodium falciparum gametocytemia in the controlled human malaria infection model. Elife 2018; 7. DOI:10.7554/eLife.31549.

    13 Vinkeles Melchers NVS, Mollenkopf S, Colebunders R, et al. Burden of onchocerciasis-associated epilepsy: first estimates and research priorities. Infect Dis Poverty 2018; 7: 101.

    14 Coffeng LE, Hermsen CC, Sauerwein RW, de Vlas SJ. The Power of Malaria Vaccine Trials Using Controlled Human Malaria Infection. PLoS Comp Biol 2017; 13: e1005255.

    15 Coffeng LE, Truscott JE, Farrell SH, et al. Comparison and validation of two mathematical models for the impact of mass drug administration on Ascaris lumbricoides and hookworm infection. Epidemics 2017; 18: 38–47.

    16 Herricks JR, Hotez PJ, Wanga V, et al. The global burden of disease study 2013: What does it mean for the NTDs? PLoS Negl Trop Dis 2017; 11: e0005424.

    17 Karimkhani C, Dellavalle RP, Coffeng LE, et al. Global Skin Disease Morbidity and Mortality: An Update From the Global Burden of Disease Study 2013. JAMA Dermatol 2017; 153: 406–12.

    18 Le Rutte EA, Chapman LAC, Coffeng LE, et al. Elimination of visceral leishmaniasis in the Indian subcontinent: a comparison of predictions from three transmission models. Epidemics 2017; 18: 67–80.

    19 Lont YL, Coffeng LE, de Vlas SJ, et al. Modelling Anti-Ov16 IgG4 Antibody Prevalence as an Indicator for Evaluation and Decision Making in Onchocerciasis Elimination Programmes. PLoS Negl Trop Dis 2017; 11: e0005314.

    20 Basáñez MG, Walker M, Turner HC, Coffeng LE, de Vlas SJ, Stolk WA. River Blindness: Mathematical Models for Control and Elimination. Adv Parasitol 2016; 94: 247–341.

    21 Karimkhani C, Wanga V, Coffeng LE, Naghavi P, Dellavalle RP, Naghavi M. Global burden of cutaneous leishmaniasis: a cross-sectional analysis from the Global Burden of Disease Study 2013. Lancet Infect Dis 2016; 3099: 3–7.

    22 Kassebaum NJ, GBD 2013 Anemia Collaborators. The Global Burden of Anemia. Hematol Oncol Clin North Am 2016; 30: 247–308.

    23 Le Rutte EA, Coffeng LE, Bontje DM, et al. Feasibility of eliminating visceral leishmaniasis from the Indian subcontinent: explorations with a set of deterministic age-structured transmission models. Parasit Vectors 2016; 9: 24.

    24 O’Hanlon SJ, Slater HC, Cheke RA, et al. Model-Based Geostatistical Mapping of the Prevalence of Onchocerca volvulus in West Africa. PLoS Med 2016; 10: e0004328.

    25 Stanaway JD, Shepard DS, Undurraga EA, et al. The global burden of dengue: an analysis from the Global Burden of Disease Study 2013. Lancet Infect Dis 2016; 3099: 1–12.

    26 Vos T, Kyu HH, Pinho C, et al. Global and national burden of diseases and injuries among children and adolescents between 1990 and 2013 findings from the global burden of disease 2013 study. JAMA Pediatr 2016; 170. DOI:10.1001/jamapediatrics.2015.4276.

    27 Coffeng LE, Bakker R, Montresor A, de Vlas SJ. Feasibility of controlling hookworm infection through preventive chemotherapy: a simulation study using the individual-based WORMSIM modelling framework. Parasit Vectors 2015; 8: 541.

    28 Goff KL, Karimkhani C, Boyers LN, et al. The Global Burden of Psoriatic Skin Disease. Br J Derm 2015; : [Epub ahead of publication].

    29 Karimkhani C, Boyers LN, Naghavi M, et al. The global burden of disease associated with alopecia areata. Br J Derm 2015; : [Epub ahead of print].

    30 Krotneva SP, Coffeng LE, Noma M, et al. African Program for Onchocerciasis Control 1995-2010: impact of annual ivermectin mass treatment on off-target infectious diseases. PLoS Negl Trop Dis 2015; 9: e0004051.

    31 Murray CJL, Barber RM, Foreman KJ, et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: Quantifying the epidemiological transition. Lancet 2015; 386. DOI:10.1016/S0140-6736(15)61340-X.

    32 Murray CJL, Barber RM, Foreman KJ, et al. Global, regional and national levels of age-specific mortality and 240 causes of death, 1990-2013 : A systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 385: 1990–2013.

    33 Stolk WA, Walker M, Coffeng LE, Basáñez M-G, de Vlas SJ. Required duration of mass ivermectin treatment for onchocerciasis elimination in Africa: a comparative modelling analysis. Parasit Vectors 2015; 8: 552.

    34 Boyers LN, Karimkhani C, Naghavi M, et al. Global mortality from conditions with skin manifestations. J Am Acad Dermatol 2014; 71: 1137-1143.e17.

    35 Coffeng LE, Stolk WA, Hoerauf A, et al. Elimination of African onchocerciasis: modeling the impact of increasing the frequency of ivermectin mass treatment. PLoS One 2014; 9: e115886.

    36 Coffeng LE, Stolk WA, Zouré HGM, et al. African Programme for Onchocerciasis Control 1995-2015: updated health impact estimates based on new disability weights. PLoS Negl Trop Dis 2014; 8: e2759.

    37 Coffeng LE. De gezondheidseffecten van onchocerciasis-bestrijding in Afrika. Tijdschr Inf 2014; 9: 7–10.

    38 Hotez PJ, Alvarado M, Basáñez M-G, et al. The Global Burden of Disease Study 2010: interpretation and implications for the neglected tropical diseases. PLoS Negl Trop Dis 2014; 8: e2865.

    39 Karimkhani C, Boyers LN, Margolis DJ, et al. Comparing Cutaneous Research Funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases with 2010 Global Burden of Disease Results. PLoS One 2014; 9: e102122.

    40 Vendrig JC, Coffeng LE, Fink-Gremmels J. Effects of orally administered galacto-oligosaccharides on immunological parameters in foals: a pilot study. BMC Vet Res 2014; 10: 278.

    41 Coffeng LE. The Health Impact of Onchocerciasis Control in Africa. 2013.

    42 Coffeng LE, Pion SDS, O’Hanlon S, et al. Onchocerciasis: the pre-control association between prevalence of palpable nodules and skin microfilariae. PLoS Negl Trop Dis 2013; 7: e2168.

    43 Coffeng LE, Stolk WA, Zouré HGM, et al. African Programme for Onchocerciasis Control 1995-2015: model-estimated health impact and cost. PLoS Negl Trop Dis 2013; 7: e2032.

    44 Vendrig JC, Coffeng LE, Fink-Gremmels J. In vitro evaluation of defined oligosaccharide fractions in an equine model of inflammation. BMC Vet Res 2013; 9: 147.

    45 Vendrig JC, Coffeng LE, Fink-Gremmels J. Effects of Separate and Concomitant TLR-2 and TLR-4 Activation in Peripheral Blood Mononuclear Cells of Newborn and Adult Horses. PLoS One 2013; 8: e66897.

    46 Coffeng LE, Fobi G, Ozoh G, et al. Concurrence of dermatological and ophthalmological morbidity in onchocerciasis. Trans R Soc Trop Med Hyg 2012; 106: 243–51.

    47 Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095–128.

    48 Murray CJL, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2197–223.

    49 Vendrig JC, Coffeng LE, Fink-Gremmels J. Equine colostral carbohydrates reduce lipopolysaccharide-induced inflammatory responses in equine peripheral blood mononuclear cells. Equine Vet J 2012; 44 Suppl 4: 68–72.

    50 Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2163–96.

    51 Coffeng LE, Visscher AJE, Ten Cate OTJ. The influence of early clinical experiences on career preference of male and female medical students. Med Teach 2009; 31: e323–6.

    52 Ter Wolbeek M, van Doornen LJP, Coffeng LE, Kavelaars A, Heijnen CJ. Cortisol and severe fatigue: a longitudinal study in adolescent girls. Psychoneuroendocrinology 2007; 32: 171–82.